CLAIMS

1. A compound, or a pharmaceutically acceptable salt thereof, said compound comprising:

    - a progastrin moiety of sequence SEQ ID NO.1 and
    - a chelating moiety,

    wherein said chelating moiety is a bifunctional chelator; and

    wherein said chelating moiety is associated with a radioisotope and wherein said progastrin moiety and said chelating moiety are covalently linked.

2. The compound or pharmaceutically acceptable salt thereof of claim 1, wherein said bifunctional chelator is selected in the list of NODAGA, NOTA, *p*-SCN-Bn-NOTA, *p*-SCN-Bn-PCTA, *p*-SCN-Bn-oxo-DO3A, desferrioxamine-p-SCN, DTPA, and TETA.

3. The compound or pharmaceutically acceptable salt thereof of any one of claims 1 or 2, wherein the bifunctional chelator is NODAGA or NOTA.

4. The compound or pharmaceutically acceptable salt thereof of any one of claims 1 to 3, wherein the bifunctional chelator is NODAGA.

5. The compound or pharmaceutically acceptable salt thereof of any one of claims 1 to 4, wherein the radioisotope is selected in the list consisting of ^{68}Ga, ^{64}Cu, ^{89}Zr, $^{186/188}$Re, ^{90}Y, ^{177}Lu, ^{153}Sm, ^{213}Bi, ^{225}Ac, ^{111}In, ^{99m}Tc, ^{123}I, or ^{223}Ra.

6. The compound or pharmaceutically acceptable salt thereof of any one of claims 1 to 5, wherein the radioisotope is ^{68}Ga or ^{64}Cu.

7. The compound or pharmaceutically acceptable salt thereof of any one of claims 1 to 6, wherein the radioisotope is ^{68}Ga.

8. A method of preparing the compound or pharmaceutically acceptable salt thereof of any one of claims 1 to 7, comprising the steps of:

    a) conjugating an amine-reactive chelating moiety to the progastrin moiety; and

b) recovering the conjugate of progastrin and chelator, or pharmaceutically acceptable salt thereof.

9. The method of claim 8, wherein the amine-reactive chelating moiety is NOTA-NHS, or NODAGA-NHS ester.

10. The method of any one of claims 8 and 9, wherein the amine-reactive chelating moiety is NODAGA-NHS ester.

11. The method of any one of claims 8 to 10, further comprising a step of:

c) incubating the conjugate of progastrin and chelator with the complementary radioisotope;

thus generating the compound or pharmaceutically acceptable salt thereof of any one of claims 1 to 7.

12. A pharmaceutical composition comprising a compound or pharmaceutically acceptable salt thereof of any one of claims 1 to 7 and a pharmaceutically acceptable carrier.

13. A kit comprising a compound or pharmaceutically acceptable salt thereof of any one of claims 1 to 7.